SUMMARY Hepatic encephalopathy (HE) is currently felt to be secondary to a disturbance in the metabolism of cerebral catecholamines with a decline in dopamine and noradrenaline and a rise in the false neurotransmitter octopamine. The aim of this study was to evaluate brain tissue levels of dopamine, noradrenaline, and octopamine in patients with cirrhosis and HE. This study includes 34 patients: 22 were cirrhotic, 12 were control subjects. Among the 22 cirrhotic patients, 19 had HE, three did not. Tissue specimens were obtained at necropsy from the locus niger, caudate nucleus, hypothalamus, thalamus and frontal cortex, and from the frontal cortex during neurosurgical procedures. Our results showed that (1) dopamine and noradrenaline levels are identical in cirrhotic patients with or without HE and in patients without liver disease (P < 0-05); (2) octopamine levels are higher in control subjects than in patients with cirrhosis and HE. In conclusion, there is no decline in dopamine and noradrenaline levels in the brain tissues of cirrhotic patients with HE. and this is in contradication with the animal findings; octopamine levels are not raised. Hepatic encephalopathy in human liver cirrhosis does not seem to be secondary to a disturbance in cerebral catecholamines.
At present some authors' think that hepatic encephalopathy (HE) is caused by an impairment in the metabolism of brain catecholamines. In normal subjects, catecholamines (dopamine and noradrenaline) carry nerve impulses across central and peripheral synapses.2 In contrast, during hepatic encephalopathy, resulting from an acute or chronic hepatic injury, the neurological manifestations could result from an accumulation of false neurotransmitters in synapses, substituting for dopamine and noradrenaline. ' Octopamine is thought to be the main false neurotransmitter.3
The purpose of this study is to measure brain catecholamine and octopamine levels in cirrhotic patients, with and without hepatic encephalopathy and compare these results with those found in normal control subjects.
Methods

PATIENTS
Studies were carried out on the following two groups:
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Results
The following data concern brain dopamine, noradrenaline, and octopamine levels.
BRAIN DOPAMINE LEVELS (Table 1) In control subjects, dopamine levels in the dopaminergic brain structures (substantia nigra, putamen, and caudate nucleus) are generally higher than those found in the noradrenergic brain structures (hypothalamus, thalamus, and frontal cortex). We demonstrated the same pattern in cirrhotic patients with hepatic encephalopathy.
Striking differences in dopamine concentrations were found in the substantia nigra. In this area, dopamine levels were higher in those patients with HE who were not receiving L dopa compared with the control group. In contrast, dopamine levels in the putamen, caudate nucleus, hypothalamus, thalamus, and frontal cortex were not statistically different in controls and cirrhotic patients whether they were receiving L dopa or not. Dopamine levels were the same in cirrhotic patients treated and not treated with L dopa.
Moreover, in two cirrhotic patients with HE and one control, brain dopamine levels remained unchanged when sampled two, four, nine, and 24 hours after death (Table 4) . BRAIN NORADRENALINE LEVELS (Table 2) In control subjects, noradrenaline levels were the same in the substantia nigra, putamen, and caudate nucleus (dopaminergic structure) and in the thalamus and frontal cortex (noradrenergic structures). However, the noradrenaline concentration was higher in the hypothalamus.
In the cirrhotic patients with HE, noradrenaline levels in the substantia nigra, putamen, and caudate nucleus were the same as those found in the thalamus and frontal cortex (Table 3) . Here again, the noradrenaline levels were higher in the hypothalamus.
Nevertheless, we found no significant differences in the brain noradrenaline concentrations between control subjects and cirrhotic patients with HE who were either treated or not treated with L dopa; this was true for the six brain areas studied. In addition, brain noradrenaline levels were the same in cirrhotic patients with HE who were treated or not treated with L dopa.
Moreover, in two cirrhotic patients with HE and one control, brain noradrenaline levels remained unchanged when sampling two, four, nine, and 24 hours after death (Table 4) Numbers of patients in parentheses.
homovanilic acid (HVA) for dopamine, and 3 methoxy 4 hydroxy phenyl glycol for noradrenaline. Measurement of the concentrations of these metabolites does not accurately reflect brain catecholamine levels. Obviously, brain samples can only be taken post-mortem, as in vivo biopsies are not justifiable in cirrhotic patients with hepatic encephalopathy. Even so, only cerebral cortex samples could be obtained.
On the other hand, the reason for the dopamine increase in the substantia nigra of the cirrhotic patients with HE as compared with control values remains obscure.
ACCURACY OF DATA
Brain catecholamine levels could conceivably be modified by the time lapse between death and the freezing of the brain samples. In both the rat,8 and man,9 brain dopamine levels decrease as this time lapse increases. However, the difference only becomes significant after six hours after death. In our study, the delay between death and sample freezing averaged two hours 45 minutes for the two groups of patients (in control subjects, the average was one hour 45 minutes, in cirrhotic patients, two hours 50 minutes). Therefore, if, in fact, brain catecholamine levels had been modified by this time lapse, it would not have been significant in either group. In addition, we were able to show, in two cirrhotic patients with hepatic encephalopathy and one control, that brain catecholamine levels remained unchanged, when sampling brain at two, four, nine, and 24 hours after death. This fact could be expected, as enzymes involved in brain catecholamine metabolism remain quite stable during this period: in rats, at 21°C, two hours after death,10 tyrosine hydroxylase and mono-aminooxydase activities fall by only 6% and 9% respectively; in contrast, during the same period, dopamine decarboxylase activity increases by 3%. Lloyd et al.11 performed a similar study on patients with Parkinson's disease: in this study the delay between death and the freezing of samples varied from two to 23 hours. These authors showed that dopamine concentrations in the putamen and caudate nucleus are lower in patients with Parkinson's disease than in the control group.
THEORY OF FALSE BRAIN NEUROTRANSMITTERS
To our knowledge, this is the first study on brain catecholamine levels in cirrhotic patients with hepatic encephalopathy. Although our findings conflict with what has already been proposed as the mechanism of both experimental12 and human cirrhotic HE,1 we found neither reduced dopamine and noradrenaline brain concentrations nor increased brain octopamine levels. Moreover, we found no correlation between the length of the coma and catecholamine levels in six brain areas. This argues against any effect of the duration of hepatic coma on brain catecholamine levels.
There are several other arguments that contradict this theory. For instance, in rats, intracerebral injections of high doses of octopamine did not elicit HE, 
